Follitropin Alfa (Genetical Recombination)

This article examines the use of Follitropin Alfa (Genetical Recombination), also known as recombinant follicle-stimulating hormone (rFSH), in clinical trials for fertility treatments. Follitropin Alfa is being studied in various contexts, including polycystic ovary syndrome (PCOS), ovarian stimulation for oocyte donation, and in women with predicted suboptimal response to ovarian stimulation. These trials aim to evaluate the effectiveness of different dosing regimens and compare Follitropin Alfa to other fertility medications.

Table of Contents

What is Follitropin Alfa?

Follitropin alfa, also known by its brand name Ovaleap, is a recombinant human follicle-stimulating hormone (FSH) used in reproductive medicine[1]. It is a genetically engineered version of the natural hormone FSH, which plays a crucial role in the development of eggs in women and sperm in men.

Medical Uses

Follitropin alfa is primarily used in the treatment of infertility. It is prescribed for:

  • Women undergoing ovarian stimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF)[2]
  • Women with anovulation (lack of ovulation)
  • Women with polycystic ovary syndrome (PCOS)[1]
  • Stimulation of spermatogenesis in men with certain types of infertility

How It Works

Follitropin alfa works by mimicking the action of natural FSH in the body. In women, it stimulates the ovaries to produce and mature eggs. In men with certain types of infertility, it can stimulate sperm production. The hormone acts on the follicle-stimulating hormone receptors in the ovaries or testes, promoting the growth and development of reproductive cells[3].

Administration

Follitropin alfa is typically administered as a subcutaneous injection. This means it is injected just under the skin, usually in the abdomen or thigh. The medication comes in pre-filled pens or vials, making it easier for patients to self-administer at home after proper training from a healthcare professional[3].

Dosage

The dosage of follitropin alfa varies depending on the individual patient and their specific condition. Based on the clinical trial information, some common dosage ranges include:

  • 50-75 IU daily for ovarian stimulation in women[1]
  • Up to 150-300 IU daily in certain protocols[3]

It’s important to note that the dosage is highly individualized and should be determined by a healthcare professional based on factors such as age, body weight, and response to treatment.

Current Clinical Trials

Several ongoing clinical trials are investigating the use of follitropin alfa in various contexts:

  • A study comparing its efficacy to letrozole in women with polycystic ovary syndrome undergoing artificial insemination[1]
  • Research on its use in oocyte donation programs[2]
  • A trial examining different doses of follitropin alfa in combination with clomiphene citrate for women with predicted suboptimal ovarian response[3]

These studies aim to optimize treatment protocols and expand our understanding of follitropin alfa’s effectiveness in various fertility treatments.

Potential Side Effects

While follitropin alfa is generally well-tolerated, some potential side effects may include:

  • Injection site reactions (redness, pain, or swelling)
  • Headache
  • Abdominal pain or bloating
  • Nausea
  • Ovarian hyperstimulation syndrome (OHSS) in rare cases

It’s important to discuss any side effects with your healthcare provider.

Important Considerations

When using follitropin alfa, keep in mind:

  • Regular monitoring through ultrasounds and blood tests is typically required during treatment to assess response and adjust dosage if necessary.
  • The medication should be used under the supervision of a fertility specialist or endocrinologist.
  • Follitropin alfa is part of a comprehensive fertility treatment plan and may be used in combination with other medications.
  • Success rates vary depending on individual factors and the specific fertility issue being addressed.

Always consult with your healthcare provider for personalized information and guidance regarding the use of follitropin alfa in your fertility treatment.

Trial Aspect Details
Conditions Studied Polycystic Ovary Syndrome (PCOS), Ovarian Stimulation for Oocyte Donation, Predicted Suboptimal Responders
Main Objectives Compare effectiveness of Follitropin Alfa to other medications, evaluate different dosing regimens, assess pregnancy rates, examine egg/embryo quality and quantity
Dosage Forms Solution for injection (300 IU/0.5 mL, 450 IU/0.75 mL, 900 IU/1.5 mL)
Administration Route Subcutaneous injection
Key Inclusion Criteria Age 18-40, specific AMH and AFC levels, BMI 18.5-30 kg/m², infertility diagnosis
Primary Endpoints Number of mature oocytes, pregnancy rates, number of good-quality blastocysts
Secondary Endpoints Embryo development timelines, blastocyst formation rates, cycle cancellation rates, cost-effectiveness

Ongoing Clinical Trials on Follitropin Alfa (Genetical Recombination)

  • Study Comparing Progesterone and Ganirelix for Preventing LH Surge in Women Undergoing Ovarian Stimulation for Egg Donation

    Recruiting

    3 1 1 1
    Spain
  • Study on Pregnancy Rates in Women with Polycystic Ovary Syndrome Using Letrozole and Gonadotropins

    Recruiting

    3 1 1 1
    Investigated diseases:
    Spain
  • Study on the Effect of Ovarian Stimulation Intensity Using Clomifene Citrate and Follitropin Alfa in Women with Infertility and Suboptimal Response

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Spain

Glossary

  • Follitropin Alfa: A genetically engineered form of follicle-stimulating hormone (FSH) used in fertility treatments to stimulate egg production in the ovaries.
  • Polycystic Ovary Syndrome (PCOS): A hormonal disorder common among women of reproductive age, characterized by irregular menstrual periods, excess androgen levels, and small collections of fluid (follicles) on the ovaries.
  • Oocyte: An immature egg cell in the ovary.
  • In Vitro Fertilization (IVF): A complex series of procedures used to help with fertility or prevent genetic problems and assist with the conception of a child.
  • Antral Follicle Count (AFC): A measure of the number of small follicles in the ovaries, used to assess ovarian reserve and predict response to ovarian stimulation.
  • Anti-Müllerian Hormone (AMH): A hormone produced by the ovaries that helps estimate ovarian reserve and predict response to fertility treatments.
  • Blastocyst: An embryo that has developed for five to seven days after fertilization, with a fluid-filled cavity and two distinct cell types.
  • Gonadotropin: A group of hormones that stimulate the gonads (testes in males, ovaries in females) to produce sex steroids and gametes.
  • Ovarian Stimulation: The use of medications to stimulate the ovaries to produce multiple eggs in a single cycle, often used in fertility treatments.
  • Suboptimal Responder: A patient who produces fewer eggs than expected in response to ovarian stimulation during fertility treatment.

References

  1. http://clinicaltrials.eu/trial/study-on-pregnancy-rates-in-women-with-polycystic-ovary-syndrome-using-letrozole-and-gonadotropins/
  2. http://clinicaltrials.eu/trial-id/2023-504188-18-00
  3. http://clinicaltrials.eu/trial/study-on-the-effect-of-ovarian-stimulation-intensity-using-clomifene-citrate-and-follitropin-alfa-in-women-with-infertility-and-suboptimal-response/